| abstract |
The present invention relates to novel antiviral active components of general formula 1, a pharmaceutical composition, an antiviral drug and a method for preventing and treating viral diseases, in particular diseases caused by the hepatitis C virus (HCV). In general formula 1, R1 is a hydrogen atom, optionally substituted C 1 –C 4 alkyl, C 6 cycloalkyl, aryl, ethoxycarbonyl, a nitro group; R2 is a hydrogen atom; R3 is N -monosubstituted or NN -disubstituted 1-methylene-piperidine-3-carboxamide of general formula 1a or N -monosubstituted or NN -disubstituted 1-methylene-piperidine-4-carboxamide of general formula 1b; R4 is a hydrogen atom, optionally substituted C 1 -C 3 alkyl; or R2 and R3 together with the carbon atoms to which they are bonded form substituted 2,3,4,9-tetrahydro-1 H -carbazole of general formula 1.1, or R2, R3 and R4 together with the atoms to which they are bonded form a substituted nitrogen heterocycle of general formula 1.2; R5 and R6 are optionally identical and are a hydrogen atom, optionally substituted C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl, or R5 and R6 together with the nitrogen atom to which they are bonded form an optionally substituted 5 or 6-membered nitrogen heterocycle which contains one or two nitrogen atoms and may be condensed with a benzene ring; R7 and R8 are hydrogen atoms, or R7 and R8 together with the carbon atom to which they are bonded form a C=O group; R9 is a nitrogen heterocycle containing at least one nitrogen atom, unsubstituted formamide, or phenyl, a substituted ethoxycarbonyl or nitro group; R10 is a hydrogen atom, optionally substituted C 1 -C 3 alkyl, substituted acetyl; n = 1 or 2; and a broken line with an accompanying continuous line ( --- ) represents a single or double bond. |